Patent ID: 7445777

Claim:
A pharmaceutical kit for treatment of retinitis pigmentosis which comprises the enzymes glutathione peroxidase (Enzyme A), prolidase (Enzyme B), glucose-6-phosphate dehydrogenase (Enzyme C) and, optionally, aldose reductase (Enzyme D) in aliquot parts and interactive quantities appropriate for administering: a) Enzyme A at a concentration generally within a range of 0.03 U.I. and 0.05 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye; b) Enzyme B, starting from the month following the last administration of Enzyme A, at a concentration generally within a range of 5 U.I. and 7 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye; c) Enzyme C, starting from the month following the last administration of Enzyme B, at a concentration generally within a range of 7 U.I. and 9 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye; and d) Enzyme D, starting from the month following the last administration of Enzyme C, at a concentration generally within a range of 7 U.I. and 9 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye.